JP2009521707A - 疾患のバイオマーカーとしての脂肪生成アデノウイルス - Google Patents

疾患のバイオマーカーとしての脂肪生成アデノウイルス Download PDF

Info

Publication number
JP2009521707A
JP2009521707A JP2008548837A JP2008548837A JP2009521707A JP 2009521707 A JP2009521707 A JP 2009521707A JP 2008548837 A JP2008548837 A JP 2008548837A JP 2008548837 A JP2008548837 A JP 2008548837A JP 2009521707 A JP2009521707 A JP 2009521707A
Authority
JP
Japan
Prior art keywords
adenovirus
cancer
adipogenic
subject
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008548837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009521707A5 (https=
Inventor
リチャード エル． アトキンソン，
Original Assignee
オーベテック， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オーベテック， エルエルシー filed Critical オーベテック， エルエルシー
Publication of JP2009521707A publication Critical patent/JP2009521707A/ja
Publication of JP2009521707A5 publication Critical patent/JP2009521707A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
JP2008548837A 2005-12-27 2006-12-27 疾患のバイオマーカーとしての脂肪生成アデノウイルス Pending JP2009521707A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75340205P 2005-12-27 2005-12-27
PCT/US2006/062632 WO2007120362A2 (en) 2005-12-27 2006-12-27 Adipogenic adenoviruses as a biomarker for disease

Publications (2)

Publication Number Publication Date
JP2009521707A true JP2009521707A (ja) 2009-06-04
JP2009521707A5 JP2009521707A5 (https=) 2009-09-10

Family

ID=38610014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008548837A Pending JP2009521707A (ja) 2005-12-27 2006-12-27 疾患のバイオマーカーとしての脂肪生成アデノウイルス

Country Status (11)

Country Link
US (5) US7442511B2 (https=)
EP (2) EP1977009B1 (https=)
JP (1) JP2009521707A (https=)
KR (1) KR20080114683A (https=)
CN (1) CN101389768B (https=)
AU (1) AU2006342053A1 (https=)
BR (1) BRPI0620755A2 (https=)
CA (1) CA2635269A1 (https=)
MX (1) MX2008008453A (https=)
RU (1) RU2008130893A (https=)
WO (1) WO2007120362A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507418B2 (en) * 2005-09-09 2009-03-24 Obetech, Llc Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes
US7442511B2 (en) * 2005-12-27 2008-10-28 Obetech, Llc Adipogenic adenoviruses as a biomarker for disease
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
JP2009156254A (ja) * 2007-12-05 2009-07-16 Ibiden Co Ltd 排気ガス処理体の保持シール部材及び排気ガス処理装置
CN102015651B (zh) 2008-03-03 2014-12-31 Irm责任有限公司 作为tlr活性调节剂的化合物和组合物
WO2010011440A2 (en) * 2008-06-16 2010-01-28 Obetech Llc Diagnosis and treatment of lipogenic adenovirus infection associated with adipose tissue hypertrophy
JP5867952B2 (ja) 2009-06-10 2016-02-24 ノバルティス アーゲー ベンゾナフチリジン含有ワクチン
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
WO2011050299A2 (en) * 2009-10-22 2011-04-28 Obetech Llc Adenovirus infection in animals
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
US8591412B2 (en) * 2009-11-18 2013-11-26 Nohands, Llc Method and system for preventing virus-related obesity and obesity related diseases
BR112012014624A8 (pt) 2009-12-15 2017-12-26 Novartis Ag suspensão homogênea de compostos de imunopotenciação e usos dos destes
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
WO2011119915A2 (en) * 2010-03-25 2011-09-29 Obetech Llc Method for detecting lipogenic adenovirus
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US8951980B2 (en) * 2010-07-08 2015-02-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Adenovirus Ad36 E4 orf1 protein for prevention and treatment of non-alcoholic fatty liver disease
WO2012006550A2 (en) * 2010-07-09 2012-01-12 Obetech Llc Methods and compositions for treatment of lipogenic virus related conditions
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
BR112015018014A2 (pt) 2013-02-01 2017-07-11 Glaxosmithkline Biologicals Sa liberação intradérmica de composições imunológicas compreendendo agonistas do receptor do tipo toll
US9925254B2 (en) 2014-11-05 2018-03-27 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against Campylobacter jejuni
JP7362667B2 (ja) 2018-02-12 2023-10-17 イニミューン・コーポレーション Ｔｏｌｌ様受容体リガンド
AU2019352906B2 (en) * 2018-10-05 2026-01-22 Minomic International Ltd. Biomarker combinations for determining aggressive prostate cancer
JP2023547677A (ja) 2020-11-04 2023-11-13 エリゴ・バイオサイエンス キューティバクテリウム・アクネス組換えファージ、その産生方法及び使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044946A1 (en) * 1997-04-04 1998-10-15 Obetech, Llc Viral obesity methods and compositions
JP2000072800A (ja) * 1998-08-26 2000-03-07 Toagosei Co Ltd 抗アデノウイルス３７型モノクローナル抗体及びその用途
JP2005341969A (ja) * 1993-03-17 2005-12-15 Usa Government 小胞体シグナル配列ペプチドと少なくとも１個の他のペプチドをエンコードする核酸配列を含有する免疫原性キメラ、及びこのキメラのワクチン及び疾患の治療における使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632013C (en) * 2005-11-30 2013-02-26 Wayne State University Adenovirus 36 e4 orf 1 gene and protein and their uses
US7442511B2 (en) * 2005-12-27 2008-10-28 Obetech, Llc Adipogenic adenoviruses as a biomarker for disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005341969A (ja) * 1993-03-17 2005-12-15 Usa Government 小胞体シグナル配列ペプチドと少なくとも１個の他のペプチドをエンコードする核酸配列を含有する免疫原性キメラ、及びこのキメラのワクチン及び疾患の治療における使用
WO1998044946A1 (en) * 1997-04-04 1998-10-15 Obetech, Llc Viral obesity methods and compositions
US6127113A (en) * 1997-04-04 2000-10-03 Obetech, Llc Viral obesity methods and compositions
US6664050B1 (en) * 1997-04-04 2003-12-16 Obetech, Llc Viral obesity methods and compositions
JP2000072800A (ja) * 1998-08-26 2000-03-07 Toagosei Co Ltd 抗アデノウイルス３７型モノクローナル抗体及びその用途

Also Published As

Publication number Publication date
US7442511B2 (en) 2008-10-28
US7910310B2 (en) 2011-03-22
CN101389768A (zh) 2009-03-18
US7745110B2 (en) 2010-06-29
KR20080114683A (ko) 2008-12-31
EP1977009A2 (en) 2008-10-08
RU2008130893A (ru) 2010-02-10
WO2007120362A3 (en) 2008-08-14
BRPI0620755A2 (pt) 2011-11-22
WO2007120362A2 (en) 2007-10-25
US20070218081A1 (en) 2007-09-20
US20090087833A1 (en) 2009-04-02
US20090087455A1 (en) 2009-04-02
US20110189235A1 (en) 2011-08-04
EP1977009B1 (en) 2016-08-17
US20130323273A1 (en) 2013-12-05
AU2006342053A1 (en) 2007-10-25
CA2635269A1 (en) 2007-10-25
EP1977009A4 (en) 2009-06-03
CN101389768B (zh) 2015-11-25
EP2390372A1 (en) 2011-11-30
MX2008008453A (es) 2008-11-28

Similar Documents

Publication Publication Date Title
US7910310B2 (en) Adipogenic adenoviruses as a biomarker for disease
USRE42129E1 (en) Viral obesity methods and compositions
CN106399555A (zh) 一种实时荧光定量pcr检测方法及其标准品和检测试剂盒
CN112266983B (zh) 一种用于检测人乳头瘤病毒hpv16和hpv18的探针组及其试剂盒
WO2021004372A1 (zh) 二甲双胍在治疗kras突变型结直肠癌中的应用
US20090220946A1 (en) Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes
WO2010011440A2 (en) Diagnosis and treatment of lipogenic adenovirus infection associated with adipose tissue hypertrophy
Egg et al. The Controversial Link Between Human Papillomavirus Infection and Esophageal Health: An Exploratory Translational Study
Maliye et al. Evaluation of human papillomavirus as a risk factor in prostate cancer pathogenesis
CN105648103B (zh) Vsig10l基因作为肺鳞癌转移诊治标志物的用途
Zamora et al. Inflammation and Current HPV Status in Head and Neck Malignancy
CN114921549B (zh) 乳腺癌生物标志物znf662基因及其检测方法与应用
CN108754030A (zh) 一种人ki多瘤病毒的荧光定量pcr引物和探针及其应用
CN109266736A (zh) 用于骨质疏松症早期筛查的分子标记物及其应用
JP2009247309A (ja) シスプラチン耐性遺伝子診断方法及びシスプラチン治療効果遺伝子診断キット
KR20190097155A (ko) Hpv 16 양성 암종의 치료 조절을 위한 혈청학적 검사
US20120244187A1 (en) Adenovirus Infection In Animals
CN120629571A (zh) Lepr基因或蛋白作为靶标在制备胆管细胞癌治疗产品中的用途
CN113322320A (zh) 一种长非编码rna及其在诊断及治疗神经胶质瘤中的应用
Hei et al. MicroRNA-370 Targets Forkhead Box M1 Regulates Migration and Invasion in Colorectal Cancer Cells
Bulane Detection of human papillomavirus types in head and neck squamous cell carcinoma
JP2022513152A5 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20111226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120814